1. Articles in category: PubMed

    1-24 of 757 1 2 3 4 ... 30 31 32 »
    1. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      Drug Deliv Transl Res. 2017 Apr 21;:

      Authors: Gilabert-Oriol R, Chernov L, Anantha M, Dragowska WH, Bally MB

      Abstract Topotecan is a drug that is under investigation for the treatment of neuroblastoma and has been encapsulated into liposomes to improve its therapeutic efficacy.

      Read Full Article
      Mentions: Treatment
    2. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      Clin Cancer Res. 2017 Apr 21;:

      Authors: Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN

      Read Full Article
    3. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

      Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

      Mol Oncol. 2017 Apr 22;:

      Authors: Tucker ER, Tall JR, Danielson LS, Gowan S, Jamin Y, Robinson SP, Banerji U, Chesler L

      Read Full Article
      Mentions: ALK
    4. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349

      Authors: Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL

      Abstract BACKGROUND: Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi-modality intensive therapy.

      Read Full Article
      Mentions: MIBG
    5. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.

      Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.

      Cancer Med. 2017 Apr 21;:

      Authors: Maser T, Rich M, Hayes D, Zhao P, Nagulapally AB, Bond J, Saulnier Sholler G

      Abstract Catechol-O-methyltransferase (COMT) is an enzyme that inactivates dopamine and other catecholamines by O-methylation.

      Read Full Article
    6. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Exp Biol Med (Maywood). 2017 Jan 01;:1535370217706952

      Authors: Cooper JP, Reynolds CP, Cho H, Kang MH

      Abstract Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells.

      Read Full Article
    7. Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

      Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

      Elife. 2017 Apr 20;6:

      Authors: Wang HQ, Halilovic E, Li X, Liang J, Cao Y, Rakiec DP, Ruddy DA, Jeay S, Wuerthner JU, Timple N, Kasibhatla S, Li N, Williams JA, Sellers WR, Huang A, Li F

      Read Full Article
      Mentions: ALK MYCN
    8. A single center clinical analysis of children with high-risk neuroblastoma.

      A single center clinical analysis of children with high-risk neuroblastoma.

      Oncotarget. 2017 Mar 07;:

      Authors: Tian X, Cao Y, Wang J, Yan J, Tian Y, Li Z, Wang H, Duan X, Jin Y, Zhao Q

      Abstract The current multidisciplinary treatment for patients with high-risk neuroblastoma (NB) is the common census. However, protocols and opinions are different in different regions and institutions.

      Read Full Article
      Mentions: Treatment LDH
    9. TIAM1 variants improve clinical outcome in neuroblastoma.

      TIAM1 variants improve clinical outcome in neuroblastoma.

      Oncotarget. 2017 Apr 03;:

      Authors: Sanmartín E, Yáñez Y, Fornés-Ferrer V, Zugaza JL, Cañete A, Castel V, Font de Mora J

      Abstract Identification of tumor driver mutations is crucial for improving clinical outcome using a personalized approach to the treatment of cancer.

      Read Full Article
      Mentions: Treatment ALK MYCN
    10. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.

      YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.

      Oncotarget. 2017 Mar 15;:

      Authors: Yang C, Tan J, Zhu J, Wang S, Wei G

      Abstract The transcriptional co-activator Yes-associated protein (YAP) is essential for Hippo pathway-driven tumorigenesis in various cancers. However, the expression and function of YAP in neuroblastoma remains elusive. Here, we show that YAP was highly expressed in Neuroblastoma (NB) and expression levels correlated with advanced tumor staging.

      Read Full Article
    11. Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA.

      Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA.

      Pediatr Res. 2017 Apr 18;:

      Authors: Duong C, Yoshida S, Chen C, Barisone G, Diaz E, Li Y, Beckett L, Chung J, Antony R, Nolta J, Nitin N, Satake N

      Abstract BACKGROUND: Neuroblastoma is the second most common extracranial cancer in children.

      Read Full Article
    12. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      J Control Release. 2017 Apr 12;:

      Authors: Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Mar Ferrandiz M, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, Sosnik A, Carcaboso AM

      Read Full Article
    13. High-risk neuroblastoma in a sub-Saharan African country: telling it like it is.

      High-risk neuroblastoma in a sub-Saharan African country: telling it like it is.

      Trop Doct. 2017 Jan 01;:49475517704363

      Authors: Hadley GP, van Heerden J

      Abstract Neuroblastoma is uncommon in Africa, but when seen usually presents as high-risk disease with a poor prognosis. This aggressive biology of the tumour is frequently augmented by delayed presentation.

      Read Full Article
    14. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      Int J Oncol. 2017 Apr 07;:

      Authors: Horwacik I, Rokita H

      Abstract Children diagnosed with high risk neuroblastoma have poor prognosis which stimulates efforts to broaden therapies of the neoplasm. GD2-ganglioside (GD2) marks neuroblastoma cells and is a target for monoclonal antibodies.

      Read Full Article
      Mentions: Antibody Treatment
    15. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

      PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

      Oncogene. 2017 Apr 10;:

      Authors: Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G

      Read Full Article
      Mentions: MYCN
    16. Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567

      Authors: McGinty L, Kolesar J

      Abstract PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.

      Read Full Article
      Mentions: Treatment
    17. Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.

      Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.

      Int J Oncol. 2016 Dec;49(6):2319-2330

      Authors: Liu L, Li Y, Xiong X, Qi K, Zhang C, Fang J, Guo H

      Abstract This study investigated arsenic trioxide (As2O3), cisplatin (DDP) and etoposide (Vp16) on the anticancer effects and P-glycoprotein (P-gp) expression in neuroblastoma (NB) SK-N-SH cells.

      Read Full Article
    18. Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.

      Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.

      Jpn J Clin Oncol. 2016 Jul;46(7):661-6

      Authors: Iehara T, Yagyu S, Tsuchiya K, Kuwahara Y, Miyachi M, Tajiri T, Sugimoto T, Sawada T, Hosoi H

      Abstract BACKGROUND: It remains unclear whether a residual tumor mass following therapy influences the prognosis of neuroblastoma.

      Read Full Article
      Mentions: MIBG
    19. Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma.

      Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma.

      J Pediatr Hematol Oncol. 2017 Apr 03;:

      Authors: Coulter DW, Boettner AD, Kortylewicz ZP, Enke SP, Luther JA, Verma V, Baranowska-Kortylewicz J

      Abstract Blood-based biomarkers are important in the detection of the disease and in the assessment of responses to therapy.

      Read Full Article
      Mentions: MYCN Biomarkers
    20. MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma.

      MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma.

      Cancer Cell Int. 2017;17:43

      Authors: Yue ZX, Huang C, Gao C, Xing TY, Liu SG, Li XJ, Zhao Q, Wang XS, Zhao W, Jin M, Ma XL

      Read Full Article
      Mentions: MYCN Bone Marrow LDH
    21. Management of Neuroblastoma: ICMR Consensus Document.

      Management of Neuroblastoma: ICMR Consensus Document.

      Indian J Pediatr. 2017 Apr 03;:

      Authors: Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, Rath GK, Bakhshi S

      Abstract Neuroblastoma (NBL) is the most common extra-cranial solid tumor in childhood. High-risk NBL is considered challenging and has one of the least favourable outcomes amongst pediatric cancers.

      Read Full Article
      Mentions: Staging Relapse MYCN
    22. Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy.

      Physical and social characteristics and support needs of adult female childhood cancer survivors who underwent hormone replacement therapy.

      Int J Clin Oncol. 2017 Mar 31;:

      Authors: Tomioka A, Maru M, Kashimada K, Sakakibara H

      Abstract BACKGROUND: Female childhood cancer survivors who develop gonadal dysfunction require female hormone replacement therapy (HRT) from puberty until menopause. However, the support provided in such cases has not been studied.

      Read Full Article
    1-24 of 757 1 2 3 4 ... 30 31 32 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (8 articles) MYCN
    2. (5 articles) ALK
    3. (3 articles) Antibody
    4. (2 articles) LDH
    5. (1 articles) Biomarkers
    6. (1 articles) Nanoparticles
    7. (1 articles) Tumorigenesis
    8. (1 articles) Bone Marrow
  4. General Informations in the News

    1. (5 articles) Treatment
    2. (2 articles) Staging
  5. Treatments in the News

    1. (2 articles) MIBG
    2. (1 articles) Refractory
    3. (1 articles) Relapse